Skip to main content
. 2012 Sep 27;4:127–139. doi: 10.2147/DHPS.S26580

Table 2.

Incidence of all-causality constipation in fixed-dose Phase III studies in OAB patients

Constipation severity Darifenacin 7.5 mg/day
N = 337
Darifenacin 15 mg/d
N = 334
Tolterodine 4 mg/d
N = 223
Placebo
N = 388
Mild, N (%) 29 (8.6) 39 (11.7) 15 (6.7) 15 (3.9)
Moderate, N (%) 19 (5.6) 23 (6.9) 9 (4.0) 7 (1.8)
Severe, N (%) 2 (0.6) 9 (2.7) 4 (1.8) 2 (0.5)
Total 50 (14.8) 71 (21.3) 28 (12.6) 24 (6.2)

Abbreviation: OAB, overactive bladder.